Project Eleven | $20,000,000 | (Jan 16, 2026)
CYB3R OPERATIONS | $5,400,000 | (Jan 16, 2026)
Quadric | $30,000,000 | (Jan 16, 2026)
Octave (US)
United States
- Menlo Park, California
- 27/07/2023
- Series B
- $30,000,000
Octave’s Precision Care Solution is the first-of-its-kind that accurately and objectively measures, and helps manage, complex and high-cost neurodegenerative diseases, starting with multiple sclerosis. Octave developed the first and only multivariate blood test to measure MS disease activity, enhanced MRI analytics and protocols, and a digital clinical program with Octave MS care partners to provide continuity of care.
Provider: The solution provides neurologists with a longitudinal and holistic perspective of the patient along with comprehensive and actionable insights, enabling more confident and informed care decisions.
Payer: The integrated and multi-dimensional approach allows payers to reduce total cost of care by optimizing healthcare medications and utilization (hospitalizations, ER visits, MRIs, labs).
Pharma: Octave enables pharma to optimize the entire lifecycle of drug discovery & development as well as clinical trials and post marketing with real world evidence.
Through purposeful problem solving and innovative technologies, Octave’s platform generates, analyzes and combines data to create a new paradigm of MS care, leading to improved patient outcomes.
- Industry Biotechnology Research
- Website https://www.octavebio.com/
- LinkedIn https://www.linkedin.com/company/octave-bio/people/
GovDash | $30,000,000 | (Jan 16, 2026)
RouteSense | $2,000,000 | (Jan 16, 2026)
Vista AI | $29,500,000 | (Jan 16, 2026)
depthfirst | $40,000,000 | (Jan 16, 2026)
Slips | $3,500,000 | (Jan 16, 2026)
FOVC | $2,000,000 | (Jan 16, 2026)
VoiceRun | $5,500,000 | (Jan 16, 2026)
Emversity | $30,000,000 | (Jan 16, 2026)
Ammobia | $7,500,000 | (Jan 16, 2026)
Pinch AI | $5,000,000 | (Jan 16, 2026)